Category

Daily Briefs

Daily Brief United States: NVIDIA Corp, Intel Corp, Advanced Micro Devices, Evolent Health Inc A, Solana, Bicara Therapeutics, Crude Oil, Tejon Ranch and more

By | Daily Briefs, United States

In today’s briefing:

  • [Q2 Earnings Preview] NVIDIA To Maintain AI GPU Leadership As Revenues Surge
  • Activist Investors Circling Intel? The Reasons Behind The Chipmaker’s Defensive Strategy!
  • AMD’s Latest Acquisition Of ZT Systems: A Challenge to NVIDIA’s AI Dominance?
  • Upgrading Utilities to Overweight; Expecting $SPX to Roll Over; NVDA and SMH Topping?
  • Evolent Health: Why This Healthcare Player Is Now a Hot Acquisition Target? – Major Drivers
  • Crypto Crisp: Where Are the Memecoins? Solana Asks
  • Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC
  • Episode 81: Chatting With AMD’s Forrest Norrod EVP Datacenter Solutions about Buying ZT Systems
  • US Rig Count Drops for Second Consecutive Week as Gas Rigs Dip
  • TRC: Believe Demand For Added TRCC Space Strong, Continue to View CEO Search as Opportunity


[Q2 Earnings Preview] NVIDIA To Maintain AI GPU Leadership As Revenues Surge

By Uttkarsh Kohli

  • NVIDIA’s dominance in AI GPUs, with 80% market share, has driven data center revenue growth by 427% YoY, with analysts expecting a 112% YoY revenue increase to $28.68 billion.
  • NVIDIA’s GPUs are crucial for AI workloads, with significant adoption by cloud giants like AWS and Microsoft Azure. AI-specific chips are expected to drive 40% of 2024 revenue.
  • 47 out of 61 analysts rate NVIDIA a strong buy, with average 12-month price targets showing 13% upside, reflecting confidence in its AI leadership despite potential market volatility.

Activist Investors Circling Intel? The Reasons Behind The Chipmaker’s Defensive Strategy!

By Baptista Research

  • Intel Corporation, once the undisputed leader in the semiconductor industry, is currently grappling with a series of challenges that have significantly impacted its market position and share price.
  • Amidst these struggles, Intel is reportedly working with advisors like Morgan Stanley to prepare a defense against potential activist investors, a clear signal of the growing pressure the company faces.
  • The need for such a defense highlights the precarious situation Intel finds itself in—a company in the throes of operational difficulties, financial underperformance, and strategic missteps.

AMD’s Latest Acquisition Of ZT Systems: A Challenge to NVIDIA’s AI Dominance?

By Baptista Research

  • Advanced Micro Devices (AMD) has made headlines with its recent acquisition of ZT Systems for $4.9 billion, a move that signals the company’s intent to become a formidable force in the AI space.
  • As the industry leader, NVIDIA has long dominated the AI hardware market, but AMD’s latest strategic acquisition could shift the competitive landscape.
  • This acquisition is not just about expanding AMD’s capabilities; it’s about positioning the company as a viable alternative to NVIDIA in the rapidly growing AI infrastructure market.

Upgrading Utilities to Overweight; Expecting $SPX to Roll Over; NVDA and SMH Topping?

By Joe Jasper

  • The SPX is back near YTD highs and testing resistance in the 5670-5783 range, and we view this as an ideal time to reduce risk and shift to defensives.
  • We continue to believe that the SPX and Nasdaq 100 (QQQ) are going through a 1- to 4-month pullback/consolidation that could end up being a topping pattern.
  • After laying out expectations in our 8/13/24 Compass report for a bounce and test of YTD highs, we now expect SPX to roll over near current levels 

Evolent Health: Why This Healthcare Player Is Now a Hot Acquisition Target? – Major Drivers

By Baptista Research

  • Evolent Health, a prominent player in the healthcare industry, has recently garnered significant acquisition interest, making it the focus of sale talks.
  • As a company with both strengths and challenges, Evolent Health presents a complex investment thesis.
  • On the positive side, Evolent has demonstrated consistent revenue growth, a strong pipeline, and a strategic focus on delivering clinical value through its Performance Suite and Specialty Technology and Services.

Crypto Crisp: Where Are the Memecoins? Solana Asks

By Mads Eberhardt

  • Over the weekend, both Bitcoin and Ethereum reached their highest levels since the crash three weeks ago.
  • As we have emphasized repeatedly in recent weeks, we continue to anticipate a gradual yet steady recovery of the crypto market, with prices to return to their pre-crash levels over the next month.
  • Now, let us dive into this week’s top news.

Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC

By Andrei Zakharov

  • Bicara Therapeutics, a clinical-stage biotech company with focus on the treatment of patients with HPV-negative head and neck cancer, files for a $200M IPO.
  • The biotech firm was backed by Biocon Limited, India’s largest biopharmaceutical company, venture capital and investment firms, among others.  
  • I believe Bicara Therapeutics will succeed in its pivotal Phase 2/3 trial of their bifunctional antibody in combination with Keytruda (pembrolizumab) during 2025.

Episode 81: Chatting With AMD’s Forrest Norrod EVP Datacenter Solutions about Buying ZT Systems

By The Circuit

  • ZT is a large server company focused on serving hyperscalers like Microsoft and AWS
  • They design customized infrastructure products tailored to specific customer needs
  • AMD sees ZT as an asset to drive competitive advantage in the data center and AI markets, enabling them to design systems that optimize performance and efficiency.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


US Rig Count Drops for Second Consecutive Week as Gas Rigs Dip

By Suhas Reddy

  • US oil and gas rig count fell by one to 585 for the week ending 23/Aug, marking a decline in rig count for the second straight week.
  • US oil rig count was unchanged at 483, after falling by two the week prior. Gas rigs fell by one to 97, after rising by one the previous week.
  • For the week ending 16/Aug, US crude oil production rose back to its record high of 13.4m bpd, after slipping down to 13.3m bpd the week prior.  

TRC: Believe Demand For Added TRCC Space Strong, Continue to View CEO Search as Opportunity

By Zacks Small Cap Research

  • We continue to believe TRC has an opportunity to strengthen its management team and improve its interaction with public shareholders with the upcoming retirement of the CEO and search for his replacement.
  • The new CEO should steer the company on a path that creates sustainable value for shareholders.
  • We believe the 2023 appointment of Brett Brown as TRC’s new CFO added strength to the C-suite and see another opportunity for the company to improve the senior management team.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: Manjushree Technopack, Berger Paints India, Bajaj Housing Finance, Greentown China, Poly Medicure and more

By | Daily Briefs, India

In today’s briefing:

  • Manjushree Technopack Pre-IPO Tearsheet
  • NIFTY100 Low Volatility 30 Index Rebalance Preview: 4 Changes as Review Cutoff Nears
  • Bajaj Housing Finance Pre-IPO – Thoughts on Valuation
  • Morning Views Asia: AAC Technologies Holdings, China Jinmao Holdings, Greentown China
  • Poly Medicure (PLM IN): Placement to Fund Capex and M&A Initiatives Amid Favorable Demand Backdrop


Manjushree Technopack Pre-IPO Tearsheet

By Akshat Shah

  • Manjushree Technopack (MTPL IN) is looking to raise about US$360m in its upcoming India IPO. The deal will be run by Avendus, Citi, GS, JM Fin and ICICI Sec.
  • Manjushree Technopack Limited is a one stop packaging solutions provider with end-to-end capabilities (from design to delivery) across containers, preforms, caps and closures, pumps and dispensers and captive recycling capabilities.
  • It is the largest rigid plastic packaging (RPP) player in terms of installed capacity in India as of March 31, 2024, according to the Technopak Report.

NIFTY100 Low Volatility 30 Index Rebalance Preview: 4 Changes as Review Cutoff Nears

By Brian Freitas

  • The review period for the Nifty 100 Low Volatility 30 Index ends on 30 August. The changes will be announced mid-September and implemented at the close on 27 September.
  • Four potential constituent changes, volatility changes and capping changes will result in one-way turnover of 16.05% resulting in a round-trip trade of INR 14.4bn (US$172m).
  • Three of the four potential deletions will have sell flows from the NSE Nifty Next 50 Index and Nifty 100 Index trackers as well.

Bajaj Housing Finance Pre-IPO – Thoughts on Valuation

By Sumeet Singh

  • Bajaj Housing Finance (BHF IN) is looking to raise around US$830m in its upcoming India IPO.
  • BHF is a non-deposit taking housing finance company engaged in mortgage lending since FY18. Its mortgage products include home loans, loans against property, lease rental discounting and developer financing.
  • We have looked at the company’s past performance and undertaken a peer comparison in our earlier notes. In this note we talk about valuations.

Morning Views Asia: AAC Technologies Holdings, China Jinmao Holdings, Greentown China

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Poly Medicure (PLM IN): Placement to Fund Capex and M&A Initiatives Amid Favorable Demand Backdrop

By Tina Banerjee

  • Poly Medicure (PLM IN) raised INR10B through QIP and allotted ~5M equity shares to eligible institutional buyers. Lighthouse India Fund IV AIF has been issued 20.5% of the QIP shares.
  • The company intends to use the proceeds to fund capex and inorganic initiatives. The company is setting up three new plants, to expand offerings in high-value therapeutic areas.
  • Poly Medicure intends to acquire businesses that offer similar products, which will help the company to expand product portfolio and increase reach in various global markets.   

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Huafa Property Services Group, PDD Holdings, Trip.com Group , Nongfu Spring , Remegen , Stella International, Baidu, Evergreen Marine Corp, Bilibili , Greentown China and more

By | China, Daily Briefs

In today’s briefing:

  • Huafa Prop (982 HK)’s CCASS Movements: Nothing To See Here
  • PDD Holdings (PDD US): Earnings Call Spooks Investors. Is There More than Meets the Eye?
  • Trip.com (9961 HK): Stock Surged After 2Q24 Result, Upside Narrowed to 18%
  • Nongfu Spring (9633 HK): 1H24 Impacted by Defamation, But Finally the Public with Nongfu
  • Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China
  • The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (August 26)
  • [Baidu, Inc. (BIDU US, SELL, TP US$80) TP Change]: Baidu’s Problem Is Not All Cyclical…Maintain SELL
  • Monthly Container Shipping Tracker | Rates Up | Transpac Volume Up | Fuel Price Down (August 2024)
  • [Bilibili (BILI US, BUY, TP US$20) TP Change]: User Demographics&AI Drive China’s Video Instagram
  • Morning Views Asia: AAC Technologies Holdings, China Jinmao Holdings, Greentown China


Huafa Prop (982 HK)’s CCASS Movements: Nothing To See Here

By David Blennerhassett

  • Ahead of Huafa Property Services Group (982 HK)‘s Scheme Meeting tomorrow, the 28th August, 42.57% of shares outstanding moved out of CCASS on the 8th July.
  • One argument for Huafa trading wide-ish to terms is due to “suspicious” CCASS moves between the Offer announcement and the vote. 
  • Some investors even cite the Golden Throat Holdings (6896 HK) debacle. This is not a Golden Throat situation. Not even close. It is decidedly less interesting and benign.

PDD Holdings (PDD US): Earnings Call Spooks Investors. Is There More than Meets the Eye?

By Devi Subhakesan

  • PDD Holdings (PDD US) stock price nosedived 28.5% yesterday wiping away more than USD55 billion in market cap following Management’s call with investors.
  • During the call, the management guided towards weakening profits in the next quarters and stated that high revenue growth was unsustainable in the long term.
  • Investors however seemed to be spooked not by negative guidance on profitability/growth but by comments on impact of non-business factors and need to adapt to changing times etc.

Trip.com (9961 HK): Stock Surged After 2Q24 Result, Upside Narrowed to 18%

By Ming Lu

  • In 2Q24, total revenue increased by 14% YoY and hotel booking revenue increased by 20%.
  • We believe the company has been riding on the recovery of the travel market and will see historical high quarter in 3Q24.
  • We also believe the stock still has an upside of 18% after one day’s surge.

Nongfu Spring (9633 HK): 1H24 Impacted by Defamation, But Finally the Public with Nongfu

By Ming Lu

  • 1H24, Nongfu’s revenue growth rate fell to 8% YoY, because Wahaha launched a propaganda against Nongfu.
  • We believe the revenue growth will rise in 2H24 and 2025, as it seems that the public do not like the way Wahaha use.
  • We set an upside of 26% and a price target at HK$38 for the end of 2025.

Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

By Smartkarma Research

For our next Corporate Webinar, we are glad to welcome RemeGen’s Chief Financial Officer, Mr. Tong Shaojing.

In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Eric Wen . The Corporate Webinar will include a live Q&A session.

The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.

About RemeGen

RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.


The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (August 26)

By David Mudd


[Baidu, Inc. (BIDU US, SELL, TP US$80) TP Change]: Baidu’s Problem Is Not All Cyclical…Maintain SELL

By Ying Pan

  • BIDU reported C2Q24 top line, non-GAAP operating profit and GAAP net income inline, 5.6% and 7.6% vs. our estimate and inline, 10% and 8.4% vs. consensus. 
  • Weak economy is only part of the problem. Weak monetization exists across the entire product line. 
  • We cut the TP to US$80 and reiterate SELL rating.

Monthly Container Shipping Tracker | Rates Up | Transpac Volume Up | Fuel Price Down (August 2024)

By Daniel Hellberg

  • Backed by strong US demand, spot container rates remain very firm
  • On top of higher average freight rates, carriers now enjoying lower fuel prices
  • Dispersion of returns on carrier shares is eye-opening, only a few performed

[Bilibili (BILI US, BUY, TP US$20) TP Change]: User Demographics&AI Drive China’s Video Instagram

By Ying Pan

  • Bilibili (BILI) reported C2Q24 revenue, GAAP operating profit, and GAAP net income in-line, 7.9%, 9.9% vs. our estimates and in-line, 12%, 18% vs. consensus. 
  • BILI’s unique, urban user base and video format give it strong competitive advantage. Further, revenue from <Three Kingdom> game will be significant.
  • We raise our TP to US$20 and reiterate BUY .  

Morning Views Asia: AAC Technologies Holdings, China Jinmao Holdings, Greentown China

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Seven & I Holdings, Toyota Motor, Kioxia Holdings , Tohokushinsha Film, TSE Tokyo Price Index TOPIX, Mitsubishi Heavy Industries, Nikkei 225, Ohba Co Ltd, Restar Holdings Corporation and more

By | Daily Briefs, Japan

In today’s briefing:

  • Updates on The Couche-Tard Deal for 7&I (3382 JP)
  • Toyota Partial Offer Results – What Next?
  • Kioxia & Tokyo Metro: Japan’s Largest IPOs Since 2018 Expected This October
  • Tohokushinsha Film (2329 JP): 3D Persists Despite Strong Pushback
  • Initial Thoughts on the Kioxia IPO – Impact on SK Hynix and Samsung Electronics
  • The Key Is to Achieve Sustainable Growth Through Continuous Business Portfolio Review
  • MHI (7011 JP): Election Unlikely to Affect Defense Budget
  • EQD | What If The Nikkei 225 Pulls Back This Week? (Buy Here)
  • Ohba (9765 Jp) – 4Q Follow-Up
  • Restar (3156 JP) – Robust Start to FY3/25 and Key M&A Shift to IT Services


Updates on The Couche-Tard Deal for 7&I (3382 JP)

By Travis Lundy

  • Today saw the publication of three different articles regarding the Alimentation Couche-Tard (ATD CN) approach and offer to purchase all the shares of Seven & I Holdings (3382 JP) 
  • The first in the Nikkei said ATD could push offer a high price, even up to ¥8 trillion. The second mentioned debt financing being feasible because of prodigious cash flow.
  • The third in Bloomberg noted that 7&i had requested the government upgrade its FEFTA status to “core”, which would lead to a more burdensome/restrictive government approval process.

Toyota Partial Offer Results – What Next?

By Travis Lundy

  • Today after the close, Toyota Motor (7203 JP) reported the results of their ¥800bn Tender Offer Buyback, originally intended to repurchase 290.12mm shares from cross-holders. 
  • In the end, 343.83mm shares were tendered (53.71mm shares more than originally expected, worth about ¥150bn at Tender Price). That creates back-end “issues” which must be considered.
  • The resulting supply/demand profile is mixed, but on balance, I expect sees positive demand into the H1 earnings announcement. Watch for another buyback possibly announced then.

Kioxia & Tokyo Metro: Japan’s Largest IPOs Since 2018 Expected This October

By Dimitris Ioannidis

  • Kioxia and Tokyo Metro with valuations of ~$10bn and ~$4.6bn are expected to be listed in October 2024 and become the largest Japanese IPOs since Softbank Corp (9434 JP) in 2018.
  • Kioxia Holdings (6600 JP) is currently forecasted to fail fast entries of both Global indices due to low IPO free float. 
  • Tokyo Metro is expected to be added via fast-entry in one Global Index because of higher IPO free float. Forecasted demand of ~$140m is expected on the fifth trading day.

Tohokushinsha Film (2329 JP): 3D Persists Despite Strong Pushback

By Arun George

  • On 24 July, 3D Investment Partners proposed to privatise Tohokushinsha Film (2329 JP) through a tender at JPY600-650. 3D has extended the offer validity period from 23 to 30 August.  
  • The controlling shareholder, Mr Hisako, claims he is not a seller regardless of price. The Board goes through the motions, knowing that Mr Hisako will decide the offer’s fate. 
  • 3D’s persistence suggests that Mr Hisako’s resolve might be checked by bumping the offer. As this outcome is likely, the shares will continue to trade through terms.  

Initial Thoughts on the Kioxia IPO – Impact on SK Hynix and Samsung Electronics

By Douglas Kim

  • Kioxia is getting ready to complete its IPO in Japan as soon as in October. Kioxia’s valuation is expected to exceed JPY 1.5 trillion (about USD 10.3 billion).
  • SK Hynix’s stake in Kioxia (through Bain led consortium) is 19%. SK Hynix’s stake in Kioxia would rise to 34% if the CBs are converted into equity. 
  • The IPO of Kioxia has mixed implications for SK Hynix which is a major shareholder. However, the IPO of Kioxia has a more direct negative impact on Samsung Electronics.

The Key Is to Achieve Sustainable Growth Through Continuous Business Portfolio Review

By Aki Matsumoto

  • Overseas investors tend to invest in companies with larger market capitalization and higher profitability, and companies with higher foreign shareholdings have significantly better values in corporate governance.
  • Hitachi has been one of the most successful companies in this area, probably due to its intermittent reforms in profitability and corporate governance through engagement with overseas investors.
  • Few companies, like Hitachi, achieved sustainable growth by continuous business portfolio review. This has led to high stock price volatility for many companies that cannot enter the sustainable growth phase.

MHI (7011 JP): Election Unlikely to Affect Defense Budget

By Scott Foster

  • The next leader of Japan’s ruling LDP, who will almost certainly become prime minister in October, will probably not make major changes to the nation’s defense policy.
  • Guidance remains unchanged after 1Q results that suggest the possibility of a better than expected order flow but also a material negative impact from a stronger yen.
  • MHI’s valuation is not yet in speculative territory, but neither is it compelling. If the yen remains stable, we expect the share price to test its recent highs.

EQD | What If The Nikkei 225 Pulls Back This Week? (Buy Here)

By Nico Rosti

  • The Nikkei 225 INDEX has rebounded strongly in the past 2 weeks, there is a chance that it starts to pull back this week.
  • This insight will try to evaluate what support levels could be good to buy, assuming the index resumes its uptrend after the pullback.
  • The index could fall for 1 or 2 weeks, the current pullback pattern is bullish (i.e. buy-the-dip).

Ohba (9765 Jp) – 4Q Follow-Up

By Sessa Investment Research

  • OHBA (hereafter, the Company) reported profit lines slightly above initial forecasts.
  • In FY24/5, operating profit rose 7.4% YoY to ¥1.84 bn against its initial plan of ¥1.8 bn, with profit attributable to owners of parent (hereafter, Profit ATOP) rising 24.6% YoY to ¥1.34 bn versus its initial plan of ¥1.15 bn.
  • On the other hand, sales fell just short of plan. 

Restar (3156 JP) – Robust Start to FY3/25 and Key M&A Shift to IT Services

By Astris Advisory Japan

  • Positive numbers and strategically aligned M&A – Q1 FY3/25 results demonstrated a strong start to the FY, with most business segments performing ahead of plan.
  • Positive demand from the auto and smartphone sectors and acquisitive growth drove sales volume and improved profitability YoY.
  • The high return Eco-solutions segment also performed solidly, contributing to sales and earnings growth YoY. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Huafa Property Services Group, Nuvoton Technology, Seven & I Holdings, Toyota Motor, Kioxia Holdings , Taiwan Semiconductor (TSMC) – ADR, OCI Co, SK Square and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Huafa Property (982 HK): Buy With Both Hands
  • Yuanta/​P-Shares Taiwan Div+ ETF Rebalance Preview: Nuvoton Could Drop Some More
  • Updates on The Couche-Tard Deal for 7&I (3382 JP)
  • Toyota Partial Offer Results – What Next?
  • Kioxia IPO Early Re-Look – Better Placed This Time Around
  • Kioxia & Tokyo Metro: Japan’s Largest IPOs Since 2018 Expected This October
  • Huafa Prop (982 HK)’s CCASS Movements: Nothing To See Here
  • TSMC (2330.TT; TSM.US): 2024 Top Clients
  • KOSPI 200 December Rebalancing: Key Points to Watch for in Proactive Position Build-Up
  • Understanding Potential Issues Within SK Group from Hynix’s Kioxia CB Conversion


Huafa Property (982 HK): Buy With Both Hands

By David Blennerhassett

  • A state-owned Offeror pitching a lifetime high Offer Price – with a solid premium –  for an illiquid company? Sounds like a slam dunk.
  • Yet  property manager Huafa Property Services Group (982 HK) has perennially traded wide to Huafa Industrial Co., Ltd. Zhuhai (600325 CH)‘s terms. This is not justified. 
  • The Scheme Meeting/SGM is tomorrow (28 August), with payment on (or before) the 30 September. Or a gross/annualised return of 4%/46%. Buy here. Then buy some more. 

Yuanta/​P-Shares Taiwan Div+ ETF Rebalance Preview: Nuvoton Could Drop Some More

By Brian Freitas

  • With the review period complete, Nuvoton Technology (4919 TT) is a near certain deletion from the Yuanta/​P-Shares Taiwan Dividend Plus ETF in September.
  • Passive trackers will need to sell 20m shares in Nuvoton Technology (4919 TT). That is over 10% of float and the stock could continue to remain under pressure. 
  • The potential deletion still appears to be under positioned. There could be renewed selling in the stock over the next few weeks.

Updates on The Couche-Tard Deal for 7&I (3382 JP)

By Travis Lundy

  • Today saw the publication of three different articles regarding the Alimentation Couche-Tard (ATD CN) approach and offer to purchase all the shares of Seven & I Holdings (3382 JP) 
  • The first in the Nikkei said ATD could push offer a high price, even up to ¥8 trillion. The second mentioned debt financing being feasible because of prodigious cash flow.
  • The third in Bloomberg noted that 7&i had requested the government upgrade its FEFTA status to “core”, which would lead to a more burdensome/restrictive government approval process.

Toyota Partial Offer Results – What Next?

By Travis Lundy

  • Today after the close, Toyota Motor (7203 JP) reported the results of their ¥800bn Tender Offer Buyback, originally intended to repurchase 290.12mm shares from cross-holders. 
  • In the end, 343.83mm shares were tendered (53.71mm shares more than originally expected, worth about ¥150bn at Tender Price). That creates back-end “issues” which must be considered.
  • The resulting supply/demand profile is mixed, but on balance, I expect sees positive demand into the H1 earnings announcement. Watch for another buyback possibly announced then.

Kioxia IPO Early Re-Look – Better Placed This Time Around

By Sumeet Singh

  • Kioxia Holdings (6600 JP) aims to list in Japan by Oct 2024 at a valuation of over US$10bn, as per media reports. 
  • Kioxia is a manufacturer and a global leader in flash memory and solid state drives for smartphones, PCs, enterprise servers and data centers
  • In this note, we take an early look at the possible listing.

Kioxia & Tokyo Metro: Japan’s Largest IPOs Since 2018 Expected This October

By Dimitris Ioannidis

  • Kioxia and Tokyo Metro with valuations of ~$10bn and ~$4.6bn are expected to be listed in October 2024 and become the largest Japanese IPOs since Softbank Corp (9434 JP) in 2018.
  • Kioxia Holdings (6600 JP) is currently forecasted to fail fast entries of both Global indices due to low IPO free float. 
  • Tokyo Metro is expected to be added via fast-entry in one Global Index because of higher IPO free float. Forecasted demand of ~$140m is expected on the fifth trading day.

Huafa Prop (982 HK)’s CCASS Movements: Nothing To See Here

By David Blennerhassett

  • Ahead of Huafa Property Services Group (982 HK)‘s Scheme Meeting tomorrow, the 28th August, 42.57% of shares outstanding moved out of CCASS on the 8th July.
  • One argument for Huafa trading wide-ish to terms is due to “suspicious” CCASS moves between the Offer announcement and the vote. 
  • Some investors even cite the Golden Throat Holdings (6896 HK) debacle. This is not a Golden Throat situation. Not even close. It is decidedly less interesting and benign.

TSMC (2330.TT; TSM.US): 2024 Top Clients

By Patrick Liao


KOSPI 200 December Rebalancing: Key Points to Watch for in Proactive Position Build-Up

By Sanghyun Park

  • The momentum for getting ahead on positions with KOSPI 200 rebalancing is holding steady. With around 60% of the screening period behind us, it’s time to start preparing our positions.
  • The current rebalancing’s screened changes have a relatively lower price volatility, suggesting a stronger chance for more aggressive position build-up now compared to previous rebalancings.
  • Trading volumes vary greatly among these changes, affecting their passive impact sizes. Consider using different weights in basket trading instead of equal weights.

Understanding Potential Issues Within SK Group from Hynix’s Kioxia CB Conversion

By Sanghyun Park

  • Hynix’s potential 15% stake in Kioxia doesn’t violate the 20% rule because KFTC’s mandatory stake rule doesn’t apply to foreign investments.
  • SK Group may transfer Hynix’s 15% Kioxia stake to SK Square by splitting Hynix and merging its investment arm with SK Square for future AI investments.
  • SK Square may attract more attention than Hynix short-term, as Kioxia’s stake via Hynix could boost market expectations for value transfer to SK Square.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Utilities: Kontrol Technologies , China Oil And Gas and more

By | Daily Briefs, Utilities Sector

In today’s briefing:

  • KNR: Trading at Cash with Proven Private Market Value
  • China Oil & Gas – Earnings Flash – H1 FY 2024 Results – Lucror Analytics


KNR: Trading at Cash with Proven Private Market Value

By Atrium Research

  • Kontrol Technologies recently completed the sale of two subsidiaries for over $24M, allowing it to pay off all of its debt and reach a net cash position of $11.5M.
  • KNR plans to reinvest the proceeds into organic growth, tuck-in acquisitions and stock buybacks.
  • KNR operates in two secular growth markets, smart building technology and HVAC services, providing a backing for future organic growth.

China Oil & Gas – Earnings Flash – H1 FY 2024 Results – Lucror Analytics

By Leonard Law, CFA

China Oil & Gas (COG) has reported reasonable H1/24 results. Gross profit and EBITDA weakened slightly, mainly weighed down by lower earnings from residential connections amid the property market downturn. That said, there was slight earnings growth from the other business segments.

Leverage was broadly stable, supported by reduced capex. Liquidity was adequate, as the company drew down on its new USD 315 mn three-year syndicated loan and repaid the bridging facility. COG’s next meaningful debt maturity is in June 2026 (when the USD 300 mn notes will come due). We believe the company has options to address the bond repayment, considering its steady business operations and stable (albeit moderately weak) financial profile.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Energy/Materials: OCI Co, NAC Kazatomprom JSC, Berger Paints India, Iron Ore, Crude Oil, New Zealand Energy and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • KOSPI 200 December Rebalancing: Key Points to Watch for in Proactive Position Build-Up
  • Kazatomprom Sends Uranium Stock Flying
  • NIFTY100 Low Volatility 30 Index Rebalance Preview: 4 Changes as Review Cutoff Nears
  • [IO Weekly 2024/34] Iron Ore Recovers as Chinese Stockpiles Decline and Fed Signals Boost Sentiment
  • US Rig Count Drops for Second Consecutive Week as Gas Rigs Dip
  • New Zealand Energy Corp. (TSX-V: NZ): Unconsequential Delays to Drilling.


KOSPI 200 December Rebalancing: Key Points to Watch for in Proactive Position Build-Up

By Sanghyun Park

  • The momentum for getting ahead on positions with KOSPI 200 rebalancing is holding steady. With around 60% of the screening period behind us, it’s time to start preparing our positions.
  • The current rebalancing’s screened changes have a relatively lower price volatility, suggesting a stronger chance for more aggressive position build-up now compared to previous rebalancings.
  • Trading volumes vary greatly among these changes, affecting their passive impact sizes. Consider using different weights in basket trading instead of equal weights.

Kazatomprom Sends Uranium Stock Flying

By Money of Mine

  • Kazatomprom announced their first half 2024 results and updated 2024 guidance, with production numbers and inventory levels dropping significantly year on year.
  • Kazatomprom’s inventory levels are at nine-year lows, with only about four months of production in inventory.
  • If Kazatomprom does not hit their production targets, they may need to purchase pounds of uranium in the spot market to maintain inventory levels.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


NIFTY100 Low Volatility 30 Index Rebalance Preview: 4 Changes as Review Cutoff Nears

By Brian Freitas

  • The review period for the Nifty 100 Low Volatility 30 Index ends on 30 August. The changes will be announced mid-September and implemented at the close on 27 September.
  • Four potential constituent changes, volatility changes and capping changes will result in one-way turnover of 16.05% resulting in a round-trip trade of INR 14.4bn (US$172m).
  • Three of the four potential deletions will have sell flows from the NSE Nifty Next 50 Index and Nifty 100 Index trackers as well.

[IO Weekly 2024/34] Iron Ore Recovers as Chinese Stockpiles Decline and Fed Signals Boost Sentiment

By Pranay Yadav

  • Iron ore prices rebounded strongly last week and continued rising this week, reversing losses from the previous week’s 9% decline
  • Chinese portside inventories of iron ore fell by 2.48 million tons in August, signaling strong demand despite slower drawdowns in the final weeks
  • SGX Iron Ore options saw a 20.7% decline in volume last week, with a sharp increase in the put/call ratio from 1.56 to 2.35, indicating increased bearish sentiment

US Rig Count Drops for Second Consecutive Week as Gas Rigs Dip

By Suhas Reddy

  • US oil and gas rig count fell by one to 585 for the week ending 23/Aug, marking a decline in rig count for the second straight week.
  • US oil rig count was unchanged at 483, after falling by two the week prior. Gas rigs fell by one to 97, after rising by one the previous week.
  • For the week ending 16/Aug, US crude oil production rose back to its record high of 13.4m bpd, after slipping down to 13.3m bpd the week prior.  

New Zealand Energy Corp. (TSX-V: NZ): Unconsequential Delays to Drilling.

By Auctus Advisors

  • Commencement of drilling operating at the high impact Tariki field is likely to be delayed by two weeks.
  • This has no impact on our valuation.
  • Our unrisked NAV for the Tariki-5 well is C$4.90 per share, including C$2.50 per share for the oil target and the balance for the low risk gas target (2P reserves).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Keppel Infrastructure Trust, SK Square , Manjushree Technopack, Evergreen Marine Corp, Mitsubishi Heavy Industries, Ohba Co Ltd and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Keppel Infra Trust Placement – While the Raising Is Relatively Large, Its past Deals Have Done Well
  • Understanding Potential Issues Within SK Group from Hynix’s Kioxia CB Conversion
  • Manjushree Technopack Pre-IPO Tearsheet
  • Monthly Container Shipping Tracker | Rates Up | Transpac Volume Up | Fuel Price Down (August 2024)
  • MHI (7011 JP): Election Unlikely to Affect Defense Budget
  • Ohba (9765 Jp) – 4Q Follow-Up


Keppel Infra Trust Placement – While the Raising Is Relatively Large, Its past Deals Have Done Well

By Clarence Chu

  • Keppel Infrastructure Trust (KIT SP) is looking to raise around S$206m (US$158m) in its primary placement.
  • Proceeds will be used to pay down its bridge loan facility linked to its Ventura acquisition. KIT also appears to have secured its unitholders’ approval for the raising earlier. 
  • In this note, we run the deal through our ECM framework and comment on deal dynamics.

Understanding Potential Issues Within SK Group from Hynix’s Kioxia CB Conversion

By Sanghyun Park

  • Hynix’s potential 15% stake in Kioxia doesn’t violate the 20% rule because KFTC’s mandatory stake rule doesn’t apply to foreign investments.
  • SK Group may transfer Hynix’s 15% Kioxia stake to SK Square by splitting Hynix and merging its investment arm with SK Square for future AI investments.
  • SK Square may attract more attention than Hynix short-term, as Kioxia’s stake via Hynix could boost market expectations for value transfer to SK Square.

Manjushree Technopack Pre-IPO Tearsheet

By Akshat Shah

  • Manjushree Technopack (MTPL IN) is looking to raise about US$360m in its upcoming India IPO. The deal will be run by Avendus, Citi, GS, JM Fin and ICICI Sec.
  • Manjushree Technopack Limited is a one stop packaging solutions provider with end-to-end capabilities (from design to delivery) across containers, preforms, caps and closures, pumps and dispensers and captive recycling capabilities.
  • It is the largest rigid plastic packaging (RPP) player in terms of installed capacity in India as of March 31, 2024, according to the Technopak Report.

Monthly Container Shipping Tracker | Rates Up | Transpac Volume Up | Fuel Price Down (August 2024)

By Daniel Hellberg

  • Backed by strong US demand, spot container rates remain very firm
  • On top of higher average freight rates, carriers now enjoying lower fuel prices
  • Dispersion of returns on carrier shares is eye-opening, only a few performed

MHI (7011 JP): Election Unlikely to Affect Defense Budget

By Scott Foster

  • The next leader of Japan’s ruling LDP, who will almost certainly become prime minister in October, will probably not make major changes to the nation’s defense policy.
  • Guidance remains unchanged after 1Q results that suggest the possibility of a better than expected order flow but also a material negative impact from a stronger yen.
  • MHI’s valuation is not yet in speculative territory, but neither is it compelling. If the yen remains stable, we expect the share price to test its recent highs.

Ohba (9765 Jp) – 4Q Follow-Up

By Sessa Investment Research

  • OHBA (hereafter, the Company) reported profit lines slightly above initial forecasts.
  • In FY24/5, operating profit rose 7.4% YoY to ¥1.84 bn against its initial plan of ¥1.8 bn, with profit attributable to owners of parent (hereafter, Profit ATOP) rising 24.6% YoY to ¥1.34 bn versus its initial plan of ¥1.15 bn.
  • On the other hand, sales fell just short of plan. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Remegen , Evolent Health Inc A, Bicara Therapeutics, Poly Medicure, Actinogen Medical, WuXi XDC Cayman , Ensysce Biosciences , JTEC Corp/Osaka and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China
  • Evolent Health: Why This Healthcare Player Is Now a Hot Acquisition Target? – Major Drivers
  • Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC
  • Poly Medicure (PLM IN): Placement to Fund Capex and M&A Initiatives Amid Favorable Demand Backdrop
  • Actinogen Medical – Further positive XanaCIDD results on depression
  • WuXi XDC Cayman (2268.HK) 24H1- High Growth of ADC Market Ensures Investment Logic, but Risks Remain
  • ENSC: Substantial Federal Funds Granted
  • JTEC Corp (3446 JP) – Maintaining Long-Term Growth Targets


Smartkarma Corporate Webinar | RemeGen: An Undervalued, Leading Biotech From China

By Smartkarma Research

For our next Corporate Webinar, we are glad to welcome RemeGen’s Chief Financial Officer, Mr. Tong Shaojing.

In the upcoming webinar, Tong will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Eric Wen . The Corporate Webinar will include a live Q&A session.

The Corporate Webinar will be hosted on Thursday, 19 September 2024, 09:00 SGT.

About RemeGen

RemeGen was cofounded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, a leading traditional Chinese medicine company in China and Dr. Fang Jianmin, a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China, RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery, development, and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.


Evolent Health: Why This Healthcare Player Is Now a Hot Acquisition Target? – Major Drivers

By Baptista Research

  • Evolent Health, a prominent player in the healthcare industry, has recently garnered significant acquisition interest, making it the focus of sale talks.
  • As a company with both strengths and challenges, Evolent Health presents a complex investment thesis.
  • On the positive side, Evolent has demonstrated consistent revenue growth, a strong pipeline, and a strategic focus on delivering clinical value through its Performance Suite and Specialty Technology and Services.

Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC

By Andrei Zakharov

  • Bicara Therapeutics, a clinical-stage biotech company with focus on the treatment of patients with HPV-negative head and neck cancer, files for a $200M IPO.
  • The biotech firm was backed by Biocon Limited, India’s largest biopharmaceutical company, venture capital and investment firms, among others.  
  • I believe Bicara Therapeutics will succeed in its pivotal Phase 2/3 trial of their bifunctional antibody in combination with Keytruda (pembrolizumab) during 2025.

Poly Medicure (PLM IN): Placement to Fund Capex and M&A Initiatives Amid Favorable Demand Backdrop

By Tina Banerjee

  • Poly Medicure (PLM IN) raised INR10B through QIP and allotted ~5M equity shares to eligible institutional buyers. Lighthouse India Fund IV AIF has been issued 20.5% of the QIP shares.
  • The company intends to use the proceeds to fund capex and inorganic initiatives. The company is setting up three new plants, to expand offerings in high-value therapeutic areas.
  • Poly Medicure intends to acquire businesses that offer similar products, which will help the company to expand product portfolio and increase reach in various global markets.   

Actinogen Medical – Further positive XanaCIDD results on depression

By Edison Investment Research

New data were revealed from Actinogen Medical’s ongoing analysis of the now-completed XanaCIDD study that support the view that the company’s lead drug candidate, Xanamem, may provide consistent and durable benefits in treating depression symptoms compared to placebo. The XanaCIDD study was designed to assess a 10mg daily dose of Xanamem versus placebo in patients with major depressive disorder (MDD) over a six-week treatment period. In line with the top-line results reported on 12 August, the new data confirm that maximal treatment effects on depression on all endpoints occurred at week 10, or four weeks after the end of the six-week treatment period. The results appear to be consistent with the molecule having a durable clinical effect in terms of controlling brain cortisol and potentially exerting anti-depressant activity.


WuXi XDC Cayman (2268.HK) 24H1- High Growth of ADC Market Ensures Investment Logic, but Risks Remain

By Xinyao (Criss) Wang

  • WuXi XDC’s YoY revenue growth rate fell to double-digit while it was kept triple-digit growth rate in previous periods. How much revenue generated from backlog isn’t within WuXi XDC’s control. 
  • The significance of healthy growth of the global ADC market is that the good story of ADC CXO is able to continue. So, WuXi XDC’s short-term performance growth is guaranteed.
  • The establishment of an independent biopharmaceutical supply chain based on US national security concerns is inevitable. So, WuXi XDC’s stock price performance is more influenced by geopolitical conflicts than fundamentals. 

ENSC: Substantial Federal Funds Granted

By Zacks Small Cap Research

  • Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world.
  • Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid.
  • The company announced that it has received a $14 million grant from the NIH for the continued development of its abuse deterrent opioid-PF614-MPAR.

JTEC Corp (3446 JP) – Maintaining Long-Term Growth Targets

By Astris Advisory Japan

  • Q1-4 FY6/24 results were behind guidance, with the Optical business experiencing longer than expected customer inspection periods delaying revenue recognition.
  • The Life Science & Equipment segment made some progress with new product sales, but positive earnings contributions are still further down the road in our view.
  • The company has lowered guidance for FY6/25 and FY6/26 as previously disclosed in the rolling three-year medium-term plan. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Kioxia Holdings , Taiwan Semiconductor (TSMC) – ADR, NVIDIA Corp, LG Corp, Intel Corp, Baidu, Advanced Micro Devices, KT Corp and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Kioxia & Tokyo Metro: Japan’s Largest IPOs Since 2018 Expected This October
  • TSMC (2330.TT; TSM.US): 2024 Top Clients
  • Initial Thoughts on the Kioxia IPO – Impact on SK Hynix and Samsung Electronics
  • [Q2 Earnings Preview] NVIDIA To Maintain AI GPU Leadership As Revenues Surge
  • LG Corp: Three Key Catalysts + NAV Valuation
  • Activist Investors Circling Intel? The Reasons Behind The Chipmaker’s Defensive Strategy!
  • [Baidu, Inc. (BIDU US, SELL, TP US$80) TP Change]: Baidu’s Problem Is Not All Cyclical…Maintain SELL
  • Upgrading Utilities to Overweight; Expecting $SPX to Roll Over; NVDA and SMH Topping?
  • AMD’s Latest Acquisition Of ZT Systems: A Challenge to NVIDIA’s AI Dominance?
  • KT Corp (030200 KS): Foreign Room Drops Below Critical Level; Passive Selling to Come


Kioxia & Tokyo Metro: Japan’s Largest IPOs Since 2018 Expected This October

By Dimitris Ioannidis

  • Kioxia and Tokyo Metro with valuations of ~$10bn and ~$4.6bn are expected to be listed in October 2024 and become the largest Japanese IPOs since Softbank Corp (9434 JP) in 2018.
  • Kioxia Holdings (6600 JP) is currently forecasted to fail fast entries of both Global indices due to low IPO free float. 
  • Tokyo Metro is expected to be added via fast-entry in one Global Index because of higher IPO free float. Forecasted demand of ~$140m is expected on the fifth trading day.

TSMC (2330.TT; TSM.US): 2024 Top Clients

By Patrick Liao


Initial Thoughts on the Kioxia IPO – Impact on SK Hynix and Samsung Electronics

By Douglas Kim

  • Kioxia is getting ready to complete its IPO in Japan as soon as in October. Kioxia’s valuation is expected to exceed JPY 1.5 trillion (about USD 10.3 billion).
  • SK Hynix’s stake in Kioxia (through Bain led consortium) is 19%. SK Hynix’s stake in Kioxia would rise to 34% if the CBs are converted into equity. 
  • The IPO of Kioxia has mixed implications for SK Hynix which is a major shareholder. However, the IPO of Kioxia has a more direct negative impact on Samsung Electronics.

[Q2 Earnings Preview] NVIDIA To Maintain AI GPU Leadership As Revenues Surge

By Uttkarsh Kohli

  • NVIDIA’s dominance in AI GPUs, with 80% market share, has driven data center revenue growth by 427% YoY, with analysts expecting a 112% YoY revenue increase to $28.68 billion.
  • NVIDIA’s GPUs are crucial for AI workloads, with significant adoption by cloud giants like AWS and Microsoft Azure. AI-specific chips are expected to drive 40% of 2024 revenue.
  • 47 out of 61 analysts rate NVIDIA a strong buy, with average 12-month price targets showing 13% upside, reflecting confidence in its AI leadership despite potential market volatility.

LG Corp: Three Key Catalysts + NAV Valuation

By Douglas Kim

  • Three key catalysts for LG Corp include potential inclusion in Korea Value Up Index, an IPO of LG CNS in 1Q 2025, and an increasing probability of higher shareholder returns. 
  • An IPO of LG CNS is likely in 1Q 2025. LG CNS is currently valued at about 7 trillion won and LG Corp has a 50% stake. 
  • Our base case NAV valuation analysis of LG Corp suggests implied NAV of 15.3 trillion won or NAV per share of 96,957 won, which is 19.8% higher than current price.

Activist Investors Circling Intel? The Reasons Behind The Chipmaker’s Defensive Strategy!

By Baptista Research

  • Intel Corporation, once the undisputed leader in the semiconductor industry, is currently grappling with a series of challenges that have significantly impacted its market position and share price.
  • Amidst these struggles, Intel is reportedly working with advisors like Morgan Stanley to prepare a defense against potential activist investors, a clear signal of the growing pressure the company faces.
  • The need for such a defense highlights the precarious situation Intel finds itself in—a company in the throes of operational difficulties, financial underperformance, and strategic missteps.

[Baidu, Inc. (BIDU US, SELL, TP US$80) TP Change]: Baidu’s Problem Is Not All Cyclical…Maintain SELL

By Ying Pan

  • BIDU reported C2Q24 top line, non-GAAP operating profit and GAAP net income inline, 5.6% and 7.6% vs. our estimate and inline, 10% and 8.4% vs. consensus. 
  • Weak economy is only part of the problem. Weak monetization exists across the entire product line. 
  • We cut the TP to US$80 and reiterate SELL rating.

Upgrading Utilities to Overweight; Expecting $SPX to Roll Over; NVDA and SMH Topping?

By Joe Jasper

  • The SPX is back near YTD highs and testing resistance in the 5670-5783 range, and we view this as an ideal time to reduce risk and shift to defensives.
  • We continue to believe that the SPX and Nasdaq 100 (QQQ) are going through a 1- to 4-month pullback/consolidation that could end up being a topping pattern.
  • After laying out expectations in our 8/13/24 Compass report for a bounce and test of YTD highs, we now expect SPX to roll over near current levels 

AMD’s Latest Acquisition Of ZT Systems: A Challenge to NVIDIA’s AI Dominance?

By Baptista Research

  • Advanced Micro Devices (AMD) has made headlines with its recent acquisition of ZT Systems for $4.9 billion, a move that signals the company’s intent to become a formidable force in the AI space.
  • As the industry leader, NVIDIA has long dominated the AI hardware market, but AMD’s latest strategic acquisition could shift the competitive landscape.
  • This acquisition is not just about expanding AMD’s capabilities; it’s about positioning the company as a viable alternative to NVIDIA in the rapidly growing AI infrastructure market.

KT Corp (030200 KS): Foreign Room Drops Below Critical Level; Passive Selling to Come

By Brian Freitas

  • Foreign investors have continued buying KT Corp (030200 KS) and the stock has outperformed SK Telecom (017670 KS), though not by a lot. 
  • Foreign buying has pushed foreign room in KT Corp (030200 KS) below 3.75% and the stock could be deleted from a global index at the next rebalance.
  • There will be some interesting trading dynamics in KT Corp (030200 KS) over the next couple of months and there will be trading opportunities versus its peers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars